Otezla

Active substance apremilast
Holder Amgen
Status closed
Indication Treatment of adult patients with oral ulcers associated with Behçet’s disease (BD) who are candidates for systemic therapy. The patient has received prior treatment with a topical therapy AND with colchicine. The patient has shown to be resistant or intolerant to colchicine or has a documented contraindication against colchicine.
Public documents Approbation
  Information for the patient
  Informed Consent
Last update 31/08/2022

 

Last updated on 28/09/2022